| You are visitor 146730 |
Thursday September 2, 2010
![]() |
International Pharmaceutical Academy (IPA) is a progressive Canadian organization dedicated to be the primary provider of Quality Education and Training for the Pharmaceutical, Medical Devices, Biologics, Cosmetics, and Allied Industries.
We present experts from industry, academia and government agencies. Providing the best in educational instruction in short course formats together with carefully orchestrated workshops.
![]() |
![]() |
![]() |
![]() |
![]() |
November 2-3, 2010 - Somerset, NJ
Preliminary Outline An Important Two-Day Conference with Interactive Exercise and Case Studies on:
MEDIA SPONSOR
| More details... |
November 18-19, 2010 - Washington, DC
Program Outline
| More details... |
October 5-6, 2010 - Philadelphia, PA
COURSE OUTLINE:
| More details... |
Global Perspectives for Pharmaceutical, Biopharmaceutical and Allied Industries
Les perspectives mondiales concernant les médicaments pharmaceutiques, biopharmaceutiques et industries connexes
September 28-29, 2010 | Montreal - Canada
Le 28-29 septembre, 2010 | Montréal-Canada
Course Overview
The greatest gathering of GMP experts from across the globe addressing the current challenges of GMPs
Le plus grand rassemblement d'experts mondiaux sur les BPF, abordant les défis actuels reliés aux BPF
| More details... |
October 19-20, 2010 - Montreal,Cananda
Program Outline:
and more...
| More details... |

Health Canada is advising expectant mothers and breastfeeding women not to take the vitamin-mineral supplements Maxum Matragen or Maxum Multi-Vite by Seroyal International Inc. Maxum Multi-Vite has been approved as a vitamin-mineral supplement for only the general public but lacks the required cautionary statement on the label regarding pregnant and/or breast feeding women. The product Maxum Matragen is being promoted by the company as a prenatal supplement; however, neither product has been authorized for sale by Health Canada for use by women who are pregnant or breastfeeding. Read More
Health Canada is warning consumers that there is a small possibility that some bottles of one lot of Rofact® (rifampin), an antibiotic used to treat tuberculosis (TB) and some other infections, may contain the drug clonazepam instead of the antibiotic rifampin. The affected lot number of Rofact® is 8K5467, and the Drug Identification Number (DIN) is 00343617. Clonazepam is an anti-epileptic medication and has sedating properties. The manufacturer, Valeant Canada, is initiating a recall to the retail level. Read More
Health Canada is updating Canadians about Hydroxycut products. On May 1, 2009, the U.S. Food and Drug Administration (FDA) issued a public warning regarding certain Hydroxycut products. The FDA is advising U.S. consumers to stop using Hydroxycut products as there have been reports of liver injuries potentially associated with this product in the United States. Read More